Consultants shared promising updates on mind most cancers and metastases, together with CATNON trial outcomes and new focused remedies, throughout ASCO 2025.
Sufferers with major mind tumors and mind metastases obtained updates on their illness and potential therapy choices on the 2025 ASCO Annual Assembly. To greatest perceive the updates, specialists Dr. Joshua Okay. Sabari and Dr. Manmeet Singh Ahluwalia sat right down to delve into the important thing takeaways for these sufferers from the assembly.
The pair mentioned findings from the CATNON trial, in addition to reviewed knowledge with HER3-DXd and immunotherapy mixtures, highlighting developments which mirror on the shift towards extra focused and fewer poisonous therapy methods for this affected person inhabitants.
Sabari is the editor in chief of CURE. He additionally serves as an assistant professor within the Division of Drugs at NYU Grossman Faculty of Drugs and director of Excessive Reliability Group Initiatives at Perlmutter Most cancers Heart. Ahluwalia is a neuro-oncologist. He serves because the chief scientific officer, chief of medical oncology, deputy director and Fernandez Household Endowed Chair in Most cancers Analysis at Baptist Well being Miami Most cancers Institute.
Sabari: Hiya. I am Dr Joshua Sabari. I am a thoracic medical oncologist at NYU Langone Well being, Perlmutter Most cancers Heart in New York. I am additionally the editor in chief of CURE.
I am excited at this time to be joined by Dr. Ahluwalia, a neurooncologist, who will likely be discussing key insights and takeaways from ASCO 2025. Dr. Ahluwalia, please introduce your self.
Ahluwalia: Thanks a lot. Dr. Sabari. I am Manmeet Ahluwalia. I am a medical oncologist by coaching. I handle sufferers with mind tumors, and I function the chief of medical oncology, chief scientific officer, and deputy director of the Miami Most cancers Institute.
Sabari: So, Dr. Ahluwalia, give us a number of the key takeaways within the central nervous symptom area at ASCO 2025.
Ahluwalia: Certain. ASCO 2025, as normal, was an thrilling assembly for us in mind tumors. Once we say, “mind tumors,” we check with tumors that originate within the mind, often known as major mind tumors (sometimes glioblastoma or gliomas), or tumors known as mind metastases, that are cancers from different components of the physique which have unfold to the mind. The most typical cancers that unfold to the mind are lung most cancers — which you deal with, Dr. Sabari — breast most cancers, and melanoma.
The one summary I actually wished to spotlight at this time was the CATNON trial. This was a randomized trial performed primarily by the EORTC in Europe, with cooperation from U.S. federal cooperative teams together with NRG. It was a 750-patient research specializing in grade 3 glioma sufferers. As we all know, glioblastoma is the commonest major malignant mind tumor in america, affecting 15,000 sufferers yearly. We additionally see round 3,500 grade 3 glioma sufferers.
This trial investigated whether or not the addition of Temodar (temozolomide), the commonest chemotherapy used to deal with glioma sufferers, provides profit to radiation. Radiation is the muse of therapy for sufferers with grade 2, grade 3 and grade 5 gliomas or glioblastomas. So, this trial addressed the query: Can chemotherapy add worth to radiation?
Inside that, there was a twofold query. First, can we give concurrent chemotherapy? This implies administering chemotherapy concurrently radiation. Usually, radiation for these sufferers lasts round six weeks. The primary query was, may chemotherapy be given concurrently with this radiation? The second query was, can chemotherapy be given adjuvantly? This implies administering it after radiation is completed, sometimes 5 days each 28 days for 12 months.
What the trial principally confirmed was that there was profit from chemotherapy within the adjuvant setting. This implies sufferers can obtain radiation for six weeks, then sometimes get a four-week break, after which obtain 12 months of chemotherapy with Temodar. Crucially, there was no further profit from giving it concurrently. Why is that necessary? As a result of each time we give sufferers chemotherapy, they do expertise uncomfortable side effects.
Though Temodar is a comparatively well-tolerated chemotherapy in comparison with many others we use, it could result in low platelet counts and low blood counts. We see this in round 10% of sufferers, generally requiring a lower within the chemotherapy dose. Clearly, in neuro-oncology, like all most cancers fields, the first questions dealing with physicians when treating sufferers are: How a lot will we assist our sufferers, how lengthy will they stay with the therapy, and at what price? So, basically, this trial confirmed that these Grade III sufferers can obtain radiation upfront after which get chemotherapy after radiation, and there’s no want to provide further concurrent chemotherapy with radiation, which may generally result in elevated toxicity or uncomfortable side effects.
I believe that was a pleasant research. It additionally confirmed us that molecular profiling is necessary, and new classifiers are being developed to assist us prognosticate, that means we are able to work out which sufferers usually tend to profit from a sure chemotherapy in comparison with those that are much less seemingly. That is the Holy Grail of precision oncology, as all of us focus on. This was the summary that basically caught my eye within the major mind tumor area.
Sabari: Dr. Ahluwalia, are you able to proceed by highlighting a number of the prime trials introduced on treating mind metastases?
Ahluwalia: Now, I will transfer on to mind metastases, which is a standard problem we face within the clinic on daily basis. Virtually 200,000 sufferers in america are identified with mind metastases yearly. The three commonest cancers that unfold to the mind, as I mentioned earlier than, embody lung most cancers, breast most cancers, and melanoma, although uncommon tumors may unfold to the mind.
I will cowl two abstracts at this time. One was on HER3-DXd (patritumab deruxtecan), a brand new antibody-drug conjugate. As you recognize, there’s been loads of pleasure within the breast oncology area, particularly with a drug known as Enhertu fam-trastuzumab deruxtecan-nxki), which is really reworking outcomes for sufferers with HER2-positive breast most cancers. Equally, that is an antibody-drug conjugate, that are like “sensible bombs.” We administer it to sufferers, it attaches to a protein expressed on the floor of most cancers cells, after which the “payload” or chemotherapy is launched contained in the most cancers cells. So, it is actually precision oncology, or what we name “sensible chemotherapy,” in comparison with prior chemotherapies the place the profit got here from the chemo attacking dividing cells (sometimes most cancers cells), but it surely may additionally assault different dividing cells, corresponding to blood cells, resulting in low blood counts.
On this trial, introduced by Dr. Matthias Preusser and performed primarily in Europe, they confirmed that this HER3 antibody-drug conjugate actually supplied profit in sufferers with mind metastases from lung most cancers, with a response fee of 30%. This implies in 30% of sufferers, there was a shrinkage of greater than 30%, in line with the RANO-BM standards, a particular criterion we use for mind tumors, distinct from the RECIST standards used for the remainder of the physique. In breast most cancers, 5 out of 21 sufferers, or 23%, noticed shrinkages.
Additionally they studied one other group: sufferers with leptomeningeal illness. As you recognize, Josh, generally when most cancers spreads to the mind, it could additionally contain the liner across the mind, resulting in leptomeningeal illness, a really difficult group of sufferers to deal with. Right here, what we discovered with this antibody-drug conjugate, which was fairly thrilling, was that not less than 65% of our sufferers (two-thirds) had been capable of stay past three months, and 50% of sufferers confirmed a profit past six months. That is good, promising early knowledge. So, I’d say, concentrate on this antibody-drug conjugate; search for extra data. It is thrilling.
Then, we introduced a few of our work from SWOG, one other cooperative group, the place we checked out a mix of Opdivo (nivolumab) and Yervoy (ipilimumab). As we all know, immunotherapy has actually remodeled outcomes for sufferers with non-small cell lung most cancers and melanoma, not solely in systemic illness but in addition in mind metastases. Nevertheless, what we do not know is how sufferers with uncommon tumors that unfold to the mind behave with this mixture. As I mentioned, while you add up these uncommon tumors, they represent round 20% of cancers we see within the clinic, so it is not a small proportion. This was the DART trial, performed by SWOG, involving over 700 websites and over 700 sufferers.
Mainly, this trial confirmed that the mix of Opdivo, an immune checkpoint inhibitor focusing on the PD-1 pathway, when mixed with Yervoy, which targets the CTLA-4 pathway (a mix identified to work properly, significantly in melanoma, and likewise useful in choose teams of lung most cancers sufferers, as you recognize), benefited sufferers with uncommon tumors, each within the mind and in the remainder of the physique. The response charges, that means the shrinkages, had been round 10% to 12%, which isn’t as excessive as what we have seen in another tumor varieties. However the necessary takeaway message of this research was that the mix of immunotherapy works within the mind in addition to in the remainder of the physique. So, it was good to see that we now have new medicine working in mind metastases.
We’re having thrilling choices for our sufferers. Historically, as everyone knows, radiation was the first approach we handled these sufferers. Whereas radiation controls the tumor, it could generally result in neurocognitive uncomfortable side effects. So, what we try to do is discover whether or not we are able to use these medical therapies to assist our sufferers with mind metastases.
Sabari: Thanks in your insights. Actually thrilling to see updates in major central nervous system tumors, gliomas, in addition to in sufferers with CNS metastases. As you talked about, these are fairly frequent, and we all know that in sufferers with leptomeningeal illness (illness involving the liner of the mind), [treatment] could be very advanced to deal with. We’re additionally very excited to see that a few of these antibody drug conjugates, these sensible bombs, as you talked about, are having exercise on this setting as properly.
I need to thanks for becoming a member of us and imparting your knowledge. Additionally thanks to the CURE neighborhood, sufferers and their caregivers for listening. Thanks.
Ahluwalia: Thanks a lot for having me.
Transcript has been edited for readability and conciseness.
For extra information on most cancers updates, analysis and training, don’t overlook to subscribe to CURE®’s newsletters right here.
